Examination of the optimal lipid-lowering therapy in patients with type 2 diabetes complicated with dyslipidemia.
Latest Information Update: 06 Mar 2012
Price :
$35 *
At a glance
- Drugs Ezetimibe (Primary) ; Pravastatin (Primary)
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 06 Mar 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 21 Oct 2011 New trial record